Prehospital Tranexamic Acid Use for Traumatic Brain Injury

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-11-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: randomizationplacebohoursinjuryto determine
  Phrases that lowered it: acidthe efficacysuspectedclinicalkg
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 6 (lowers risk) · Design
• Sponsor's past termination rate: 8.1% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 89 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 97.2% (raises risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 309 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: 15 (raises risk) · Who can join
• Drug's FAERS reports with a death: 21.9% (raises risk) · Drug's FDA history
• Keywords listed: 7 (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid NCT03846973 · started 2018 · scored riskier than 77% of active trials completed
• Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial) NCT02086500 · started 2015 · scored riskier than 70% of active trials completed
• Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury NCT02535949 · started 2016 · scored riskier than 95% of active trials completed
• Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study) NCT02187120 · started 2014 · scored riskier than 52% of active trials completed
• California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA NCT03469947 · started 2015 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.